Donor Fraction Cell-Free DNA and Rejection in Adult and Pediatric Heart Transplantation

Endomyocardial biopsy (EMB) is the current standard for rejection surveillance in heart transplant recipients. Quantification of donor-specific cell-free DNA (cfDNA) may be an appropriate biomarker for non-invasive rejection surveillance. A multi-center prospective blinded study (DNA-based Transplant Rejection Test, DTRT) investigated the value of donor fraction (DF), defined as the ratio of cfDNA specific to the transplanted organ to total amount of cfDNA present in a blood sample.
Source: The Journal of Heart and Lung Transplantation - Category: Transplant Surgery Authors: Source Type: research

Related Links:

(The Society of Thoracic Surgeons) Legendary heart-lung transplant surgeon, researcher, and professor Sir Magdi Habib Yacoub, MD, today was honored with the 2020 Earl Bakken Scientific Achievement Award from The Society of Thoracic Surgeons.
Source: EurekAlert! - Medicine and Health - Category: International Medicine & Public Health Source Type: news
UCLA researchers are part of an international team that reported the use of a stem cell gene therapy to treat nine people with the rare, inherited blood disease known as X-linked chronic granulomatous disease, or X-CGD. Six of those patients are now in remission and have stopped other treatments. Before now, people with X-CGD – which causes recurrent infections, prolonged hospitalizations for treatment, and a shortened lifespan – had to rely on bone marrow donations for a chance at remission.“With this gene therapy, you can use a patient’s own stem cells instead of donor cells for a transplant,&rdqu...
Source: UCLA Newsroom: Health Sciences - Category: Universities & Medical Training Source Type: news
I read with interest the original science study by Leary et al entitled “Endothelin-1, cardiac morphology, and heart failure: the MESA angiogenesis study.1” The authors are to be congratulated for their thoughtful work pursuing the association of endothelin-1 (ET1) with cardiovascular risk in a population free from clinical cardiovascular disease at enrollment. Furt her, their counter-intuitive findings that higher ET1 were associated with higher ejection fraction and reduced risk for heart failure or cardiovascular death are thought-provoking.
Source: The Journal of Heart and Lung Transplantation - Category: Transplant Surgery Authors: Tags: Case Anecdotes, Comments and Opinions Source Type: research
We report a comprehensive analysis of stroke subtypes in the ENDURANCE (DT) and ENDURANCE Supplemental (DT2) trials.
Source: The Journal of Heart and Lung Transplantation - Category: Transplant Surgery Authors: Tags: Original Clinical Science Source Type: research
AbstractBackgroundWe previously demonstrated high diagnostic accuracy of Rubidium-82 positron emission tomography (PET) myocardial blood flow (MBF) quantification for CAV. The purpose of this study was to validate multiparametric PET detection of CAV by combined rate-pressure-product-corrected myocardial flow reserve (cMFR), stress MBF, and coronary vascular resistance (CVR) assessment.Methods and ResultsDiagnostic CAV cut-offs of cMFR  
Source: Journal of Nuclear Cardiology - Category: Nuclear Medicine Source Type: research
Publication date: Available online 25 January 2020Source: Best Practice &Research Clinical AnaesthesiologyAuthor(s): Miriam Zeillemaker - Hoekstra, Carlijn I. Buis, Vlado Cernak, Koen MEM. ReyntjensAbstractThe combined transplantation of a thoracic organ and the liver is performed in patients with dual-organ failure in whom survival is not expected with single-organ transplantation alone. Although uncommonly performed, the number of combined liver-lung and liver-heart transplants is increasing. Anesthetic management of this complex procedure is challenging. Major blood loss, prolonged operation time, difficult weaning ...
Source: Best Practice and Research Clinical Anaesthesiology - Category: Anesthesiology Source Type: research
The utilization and duration of left ventricular assist device (LVAD) support has increased steadily over the last decade and recent changes in the UNOS heart allocation system, implemented in October 2018, portend a further increase in the duration of mechanical circulatory support for many patients (1). Though four-year survival rates have improved to 60% following LVAD implantation, the leading cause of death in these patients is neurological injury, specifically ischemic and hemorrhagic stroke (spontaneous subarachnoid hemorrhage or intraparenchymal hemorrhage [IPH]) (2).
Source: The Journal of Heart and Lung Transplantation - Category: Transplant Surgery Authors: Tags: Editorial Source Type: research
Recipients of solid organ transplant (SOT) are at risk of viral infection and development of viral-driven malignancy (EBV-PTLD) due to immunosuppressive medications to prevent organ rejection. Treatments are limited by poor efficacy and organ toxicity, and reduction in immunosuppression to enable the patient's immune system fight the infection risks organ rejection. Allogeneic viral specific T-cells (VST) have been used to treat viral infections after stem cell transplant, and here we evaluated VST for the treatment of CMV, ADV, EBV-PTLD and BK in six SOT (heart, liver, kidney, lung) recipients.
Source: Biology of Blood and Marrow Transplantation - Category: Hematology Authors: Tags: 528 Source Type: research
Prior research has suggested that the prevalence and outcomes of pulmonary arterial hypertension (PAH) may vary by race or ethnicity. However, these studies have been limited by small sample size or methodological techniques relying on epidemiologic data. The purpose of this study is to evaluate the relationship between race/ethnicity and survival in a large U.S.-based prospective multicenter registry.
Source: The Journal of Heart and Lung Transplantation - Category: Transplant Surgery Authors: Tags: Original Clinical Science Source Type: research
Mechanical  circulatory support (MCS) evolved from an engineering dream to clinical reality during the 1980s when increasing numbers of patients were dying on heart transplant wait lists. Following the Randomized Evaluation of Mechanical Assistance for the Treatment of Congestive Heart Failure Trial,1 the US Food and Drug Administration (FDA) approved a pulsatile implantable left ventricular assist device (LVAD) for long-term implantation in 2002. When the FDA approved the first US continuous flow (CF) LVAD in 2008, the landscape had changed dramatically.
Source: The Journal of Heart and Lung Transplantation - Category: Transplant Surgery Authors: Tags: Adult: Mechanical Circulartory Support: AATS/ISHLT Guidelines on Selected Topics in Mechanical Circulatory Support Source Type: research
More News: Cardiology | Heart | Heart Transplant | Lung Transplant | Pediatrics | Study | Transplant Surgery | Transplants